ArticleOncology and therapy2022

Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE).

Akito Hata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.